News Hub

The Ins and Outs of In Vivo CAR Process Development: A Case Study From The ISCT Process Development and Manufacturing (PDM) Committee

  

Hannah W. Song, PhD
Contributing Editor, ISCT Telegraft
National Institutes of Health
United States



Dr. Claudia Lee, PhD, Chief Technology Officer of Velvet Therapeutics, sat down with ISCT’s Process Development and Manufacturing committee in August to discuss the intricacies of their unique in vivo CAR platform.


No matter the target or delivery modality, the manufacturing process for developing an in vivo Chimeric Antigen Receptor (CAR) therapy comes down to validating how a delivery vehicle and its cargo – for example, mRNA in a lipid nanoparticle encoding a CD19 CAR, or a lentiviral vector encoding a CD22 CAR – can be transformed into a reproducible product with defined critical quality attributes (CQAs).

During August’s Process Development and Manufacturing (PDM) Committee meeting, Lee joined other CGT industry professionals to discuss a cutting-edge case study of Velvet Therapeutics’ nanoparticle platform designed for in vivo CAR targeting solid tumors. Velvet’s platform uniquely uses DNA cargo encoding the CAR construct, complexed with a proprietary cationic polymer to form their nanoparticle therapy.

Just like any pharmaceutical, the CQAs of an in vivo CAR, like Velvet’s, must include identity, purity and potency. Let’s take these one-by-one and compare them to a traditional ex vivo CAR T-cell product.

  1. Identity. Establishing identity for a DNA-based in vivo CAR is straightforward; it’s simply confirming that the DNA sequence encodes the correct CAR target.
  2. Purity. The purity question shifts from cell-based methods like flow cytometry to nanoparticle modalities such as zeta potential and hydrodynamic radius. The purity of nanoparticles is rooted in how many effective particles can enter the cell and result in the expression of the intended construct. 
  3. Potency. Potency testing for in vivo CARs stays in a similar realm as a traditional ex vivo CAR-T cell therapy. One could easily envision a cell-based assay to confirm CAR expression, as well as cytotoxicity assays to confirm the number of viable cells after the introduction of the drug product. 

Let’s not forget, however, that in vivo CARs must validate these CQAs on much fewer batches of product compared to an autologous CAR-T cell. In addition, process developers of in vivo CARs must address the age-old topic of stability, where the variables of storage temperature, container/closure, and length of storage must be addressed. This is, of course, a crucial part of developing both in vivo and ex vivo CARs – but is easier to implement since in vivo CARs do not require extreme cold temperatures such as liquid nitrogen to maintain product stability.

Finally, if we step back and consider one of the main drawbacks of in vivo CAR compared to its ex vivo counterpart, it is that in vivo targeting sacrifices the ability to precisely deliver the CAR into a highly purified cell type, namely, T cells – although expression of CAR constructs in other cell types shows promise, such as NK cells (Nkarta Inc.) or CAR-Ms (CARisma Therapeutics). Instead, an in vivo CAR therapy is infused directly into the patient and interacts with many diverse cell types of the immune system and beyond. 

Velvet Therapeutics takes this limitation and turns it on its head – establishing evidence that delivery of CARs into non T-cell targets – particularly monocytes that differentiate into macrophages and present antigen to tumor cells – can actually be a key benefit in the context of solid tumors. That changes the equation entirely for their unique modality and disease target.

At the end of the day, a successful in vivo CAR can’t just be about scalability. At its core, it must be a successful therapeutic. But the inherent off-the-shelf capability combined with easier manufacturing logistics could unlock access for more patients. That’s what continues to drive the fields’ excitement over the future of in vivo CARs.


For more information on joining ISCT’s Process Development and Manufacturing Committee, reach out to Lydia Redmond at lydia@isctglobal.org.


#CommunityFeature

0 comments
10 views

Permalink